Your session is about to expire
← Back to Search
Weekly Paclitaxel for Breast Cancer (FB-12 Trial)
FB-12 Trial Summary
This trial will test whether neoadjuvant chemotherapy with anti-HER2 antibodies is effective in patients with HER2-negative invasive breast cancer who have abnormal HER2 signaling activity.
- HER2-negative Breast Cancer
FB-12 Trial Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.FB-12 Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- You have a lung disease that causes difficulty breathing.You have a medical condition that affects your ability to absorb nutrients or have had surgery on your stomach or small intestine that may impact digestion.You have a medical condition that prevents you from taking corticosteroids.You have mental health or addiction issues that may interfere with your ability to participate in the study.You have an ongoing infection that requires antibiotics to control.You are currently undergoing hormonal therapy for sex-related issues.You have a heart condition that would make it unsafe for you to take the study drugs.You have high blood pressure that is not being managed or controlled.You are allergic to any of the study drugs or their ingredients.You had cancer in any part of your body other than the breast, within the past 2 years before starting chemotherapy.You have a condition that prevents you from receiving the treatment or attending required follow-up visits.
- Group 1: Arm 1
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Are there any regulatory clearances for Weekly Paclitaxel?
"While there is some evidence of safety, no data exists yet to prove efficacy. Thus, the team at Power assigned Weekly Paclitaxel a score of 2 on its scale from 1-3."
Are there any existing investigations that have involved the use of Weekly Paclitaxel?
"At present, 1825 clinical trials for Weekly Paclitaxel have been launched, with 408 of those being in Phase 3. These studies are mainly conducted within Seattle, Washington but encompass 77104 different sites."
Is enrollment into this experiment open to contributors?
"Investigational data on clinicaltrials.gov states that this trial is actively recruiting participants, with the original posting having been made on May 14th 2018 and last edited on May 31st 2022."
Is this the inaugural endeavor of its type?
"Since 1997, Weekly Paclitaxel has been studied extensively. A sponsored clinical trial by Alfacell in the same year determined its efficacy and granted it Phase 3 drug approval. At present, there are 1825 active trials for this medication conducted across 3704 cities and 82 countries worldwide."
How many health centers are currently engaged in this clinical trial?
"This trial is currently acquiring participants from 43 different medical centres, located in Newark, Zanesville and York as well as other cities. It would be prudent to choose the closest site so that travelling demands are at a minimum if you decide to take part."
What is the uppermost capacity for the number of participants in this trial?
"This clinical trial is in need of 64 participants that meet the pre-determined selection criteria. These individuals may take part at either Licking Memorial Hospital, located in Newark Pennsylvania or Genesis Health Care situated in Zanesville Michigan."
Share this study with friends
Copy Link
Messenger